Metastatic Castration Sensitive Prostate Cancer (mCSPC)

DBCOND0154644Neoplasms Urogenital Diseases

Metastatic Castration Sensitive Prostate Cancer (mCSPC) is the indication for 6 drugs in DrugBank. It is covered by 10 curated, structured indications.

Also known as: Metastatic Castration Sensitive Prostate Cancer · Metastatic Castrate Sensitive Prostate Cancer · Metastatic Castration-sensitive Prostate Cancer · Metastatic Castrate-sensitive Prostate Cancer
Classified under: Neoplasms
Urogenital Diseases
Indicated drugs: Abiraterone
Apalutamide
Darolutamide
Enzalutamide
Niraparib
Prednisone

What you can answer from here — as of October 22, 2026

6Indicated drugsWith each drug's targets and mechanism

Listed above

10Structured indicationsPopulation, line of therapy, route and combination as fields, not prose

14Clinical trialsPhase, status and sponsor resolved per trial

2Drugs reporting it as an adverse effectWith incidence where the label states it

Which approved drugs for Metastatic Castration Sensitive Prostate Cancer (mCSPC) share a target, and which companies have late-stage candidates against it?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account